Aterian enters the post-earnings window with the remnants of a violent short squeeze still visible in its data — and a director who backed the stock with $3.5 million just weeks before results.
The defining move of the past three weeks was a borrow market that seized up completely. Cost to borrow climbed from a routine 2.7% on April 17 to a peak above 312% on April 30 — a roughly 100-fold increase in under two weeks — as the lending pool ran dry. Availability collapsed to effectively zero as every share in the pool was lent out. Short interest as a percentage of the free float spiked to 16.2% on April 30, the highest reading in the data window, before shorts began covering aggressively. By May 7, SI had dropped to just 0.4% of the float. The squeeze mechanics were textbook: maximum borrow cost, fully exhausted availability, rapid short covering.
That pressure has since eased materially. By May 14, SI had rebuilt to 4.6% of the float — a 522% week-on-week jump in shares short — but the lending market tells a very different story from three weeks ago. Cost to borrow has dropped to 111%, down from its 312% peak, and availability has loosened substantially. The short score, which hit 71.8 on May 4 at the height of the squeeze, has fallen to 52.2 — moderate, not extreme. The borrow market is still more expensive than normal, but the acute phase of the squeeze has passed. Shorts rebuilding here are paying elevated but manageable rates, not crisis-level fees.
The most notable non-squeeze data point is a director purchase. David Lazar bought 1.75 million shares on April 27 at $2.00 per share, a $3.5 million commitment that represents 11.7% of the company. That trade landed three days before the April 30 short interest peak and amid a stock that was already elevated — the buy therefore reads less as a value call and more as a directional bet during a period of elevated volatility. The CEO, CFO, and CTO all sold small amounts in June 2025, but those transactions were token in size (the CEO sold $60,000 worth). The Lazar purchase dwarfs all other insider activity in the trailing twelve months.
Q1 results arrived on May 15. EPS came in at -$0.39, an improvement from -$0.46 a year earlier, but the headline that matters is the revenue miss: sales were reported at $18,000 versus a consensus estimate of $15.82 million — the exact figures are difficult to reconcile (the revenue figure may reflect thousands rather than millions in the raw data feed), but the directional message from coverage was a miss. The stock fell 5.2% on the day. The prior two earnings prints both produced negative 1-day reactions: -6.1% in March 2026 and -5.0% in an earlier release, with one 5-day drift of -18.2% after the November 2025 print. The stock has not found post-earnings follow-through to the upside in any of the three prior events in the data.
Analyst coverage is extremely thin and entirely stale — the most recent rating change on record dates to May 2024, and the mean price target of $8.00 is almost certainly a historical artefact from when the stock traded at multiples of its current $1.09 level. No weight should be placed on that figure. Options positioning offers a small additional read: the put/call ratio at 0.22 is right in line with its 20-day average, with a z-score of -0.11 — essentially neutral. There is no hedging rush visible in options, which is consistent with a market that has already absorbed the shock from both the squeeze and the earnings release.
The next scheduled earnings event is May 21 — worth watching given the SEC filing of a PREM14A (preliminary proxy statement for a merger or similar corporate action) on the same day results were reported. That filing adds a dimension beyond the normal quarter-by-quarter framework.
See the live data behind this article on ORTEX.
Open ATER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
